帕比司他与地西他滨在异基因造血干细胞移植后供者淋巴细胞输注前的可行性研究
该研究评估了异基因造血干细胞移植后、供者淋巴细胞输注前早期启动帕比司他联合地西他滨表观遗传治疗的可行性。帕比司他单药或联合低剂量地西他滨方案可行,2年累积复发率35%,总生存率50%。
要点
- 帕比司他单药或联合低剂量地西他滨在allo-HSCT后早期给药可行。
- 该表观遗传治疗与相对较低的复发率相关。
- 帕比司他联合地西他滨20mg/m2方案与延长的血细胞减少无关,不可行。
核心结论
- 异基因造血干细胞移植后帕比司他单药或联合低剂量地西他滨的表观遗传治疗可行,且与相对较低的复发率相关。
研究设计与样本
- 研究纳入140例18至70岁高危AML患者,其中110例接受allo-HSCT;评估三种剂量水平的剂量限制性毒性,包括帕比司他单药20mg(第1、4、8、11天,4周周期)、帕比司他联合地西他滨20mg/m2或10mg/m2(每4周周期的第1至3天);1期后继续2期,关注方案完成和治疗结局。
主要发现
- 87例接受表观遗传治疗的患者中,23例(26%)观察到与帕比司他和地西他滨相关的3级和4级不良事件。
- 累积复发率为35%(标准误5%),24个月总生存率和无进展生存率分别为50%(标准误5%)和49%(标准误5%)。
关键数值与推荐
- 帕比司他单药和帕比司他联合地西他滨10mg/m2方案可行,帕比司他联合地西他滨20mg/m2方案与延长的血细胞减少无关。
- 累积复发率35%(标准误5%),24个月总生存率50%(标准误5%),无进展生存率49%(标准误5%)。
临床怎么用
- 对于高危AML患者,allo-HSCT后早期启动帕比司他单药或联合低剂量地西他滨的表观遗传治疗是可行的,可能降低复发率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early initiation of epigenetic therapy with panobinostat and decitabine after allo-HSCT and before donor lymphocyte infusion (DLI) in poor-risk patients with acute myeloid leukemia (AML) or refractory anemia with excess blasts with International Prognostic Scoring System score ≥1.5. A total of 140 poor-risk patients with AML aged 18 to 70 years were registered, and 110 proceeded to allo-HSCT. Three dose levels were evaluated for dose-limiting toxicities, including panobinostat monotherapy 20 mg at days 1, 4, 8, and 11 of a 4-week cycle (PNB mono group) and panobinostat combined with either decitabine 20 mg/m2 (PNB/DAC20 group) or decitabine 10 mg/m2 (PNB/DAC10 group) at days 1 to 3 of every 4-week cycle. After phase 1, the study continued as phase 2, focusing on completion of protocol treatment and treatment outcome. PNB mono and PNB/DAC10 were feasible, whereas PNB/DAC20 was not related to prolonged cytopenia. Sixty of 110 patients who underwent transplantation were eligible to receive their first DLI within 115 days after allo-HSCT. Grade 3 and 4 adverse events related to panobinostat and decitabine were observed in 23 (26%) of the 87 patients, and they received epigenetic therapy. Cumulative incidence of relapse was 35% (standard error [SE] 5), and overall survival and progression-free survival at 24 months were 50% (SE 5) and 49% (SE 5). Post-allo-HSCT epigenetic therapy with panobinostat alone or in combination with low-dose decitabine is feasible and is associated with a relatively low relapse rate. The trial was registered at the European Clinical Trial Registry, https://www.clinicaltrialsregister.eu, as ECT2012-003344-74.
引用
- Kalin B, van Norden Y, van Gelder M, et al. Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation. Blood Adv. 2020. PMID: 32936907. doi:10.1182/bloodadvances.2020002074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。